The Exosome Manufacturing Gap
Why the Biggest Crisis in EV Therapeutics Isn't Science
Dr Deepika Arora, Regenerative Cell Research Institute
Aditya Banerjee, Regenerative Cell Research Institute
The application of EVs, especially exosomes, has been recognised as potential therapeutic platforms, and hundreds of clinical trials have examined their potential applications in regenerative medicine, oncology, and immunotherapy. However, although promising preclinical and early clinical data exist, none of the EV-based therapeutic products have yet been commercialised. These challenges include the lack of standardised isolation methods, scalable GMP-compliant manufacturing processes that ensure product consistency, and a limited understanding of the in vivo pharmacokinetics of extracellular vesicles (EVs). In this article, the authors emphasize the manufacturing challenges that have hindered the development of high-quality EV therapeutics and outline the technological and quality-related advancements needed to bring the first commercially viable EV-based drug to market.
Introduction: The Promise and the Paradox
Extracellular vesicles (EVs) including exosomes, have been touted as the next big thing in the biopharmaceuticals arena for the last decade. Exosomes are naturally occurring vesicles of nanosized (30-150 nm) which are secreted by almost all eukaryotic cells. The exosomes have been differentiated from other vesicles, including apoptotic bodies, at the molecular level from their biogenesis pathway. Formed in the endosomal compartment through the fusion of multivesicular bodies with the plasma membrane, their unique origin results in highly specific bioactive cargos- including lipids, proteins, microRNA and mRNA, selectively sorted by parent cell.
The advanced biological framework makes exosomes highly efficient in delivering precise messages to regulate intricate processes such as immune function modulation, angiogenesis, and tissue renewal. Natural exosomes are highly biocompatible, have an extremely low immunogenicity, and are naturally able to cross highly permeable biological barriers, such as the blood-brain barrier, in comparison to synthetic delivery systems, like liposomes or synthetic lipid nanoparticles (LNPs).
This immense potential has driven substantial investments, with the therapeutic utility of EVs in regenerative medicine, targeted oncology, and immune modulation is being explored in hundreds of clinical trials. However, the f presents a glaring paradox: although preclinical and early-stage clinical trials are promising, none of these EV- based therapeutic products have successfully reached the market yet .
The barrier to entry is now non- biological , driven instead by scalable manufacturing, and regulatory hurdles and bioprocessing science. The biopharmaceutical industry faces severe challenges – including a lack of standardized isolation procedures, scalable Good Manufacturing Practice (GMP)-compliant production, limited understanding of in vivo behavior - collectively known as the ‘manufacturing gap’.
The Upstream Bottleneck: Scalable Cell Culture
The therapeutic exosomes manufacturing pipeline begins upstream, aiming to produce enough EVs to meet broad clinical and commercial demands. While traditional 2D static cultures (such as a T-flasks) suffice for academic bench research, they are entirely unfeasible for industrial production. . Because a single human dose can require trillions of exosomes, advanced, high-yield cell culture methodologies capable of processing thousands of liters are essentials.
Moving to three-dimensional (3D) stirred-tank bioreactors is essential to produce the therapeutic quantities needed for late-stage trials and market distribution (Ahn et al., 2022). However, scaling up presents complex engineering hurdles. When using large scale systems for adherent cells, microcarriers are often required for cell attachment. Agitation subjects these microcarriers to hydrodynamic shear stress, which can induce phenotypic changes and alter exosomes molecular profiles.
Optimising these environments requires precise monitoring of dissolved oxygen, pH, nutrient feeding, and agitation. Additionally, shifting away from fetal bovine serum (FBS)—which introduces immunogenic animal contaminants—toward scalable, GMP-compliant, serum-free, and xeno-free media is critical to ensure safety.
An Introduction to Downstream Dilemma: Isolation and Purification at Scale
Following upstream production, developers face the challenge of downstream processing: isolating and purifying intact EVs from biological fluids. While differential ultracentrifugation (UC) remains the long-standing gold standard in academic research, isolation techniques span five main categories (ultracentrifugation, size-based methods, immunoaffinity capture, precipitation, and microfluidics).
Differential ultracentrifugation (UC) uses extreme centrifugal forces (up to 200,000 \times g) to pellet vesicles and has long been considered the academic gold standard for exosome separation. However, UC is labor-intensive, time-consuming, low-throughput, and inadequate for industrial use, often causing exosome aggregation, vesicle injury, and co-isolation of impurities (Ahn et al., 2022).
To overcome this manufacturing deficit, the biopharmaceutical industry is shifting toward scalable methods with higher purity, such as normal flow filtration (NFF) and tangential flow filtration (TFF) for volume reduction without destructive shear forces. Furthermore, chromatography techniques like size exclusion chromatography (SEC) and anion exchange chromatography (AIEX)—which exploits the negative electrostatic charge of exosome surface glycans—are promising tools for high-resolution purification (Ahn et al., 2022).
In addition to its roles in the synthesis of small molecules and biological entities, chromatography has become an essential biomanufacturing tool for high-resolution purification. Size exclusion chromatography (SEC) and anion exchange chromatography (AIEX) are especially promising techniques, with AIEX utilising the negative electrostatic charge on the exosome surface glycans and functional groups to precisely separate exosomes from non-vesicular proteins and process-related impurities without conventional separation techniques (Ahn et al., 2022).
Yet, none of these technologies is currently able to provide a complete package of high yield, absolute purity and ease of operation. Today, low extraction yields, high capital costs and a lack of methodological standardisation overall remain as challenges for the application of EVs in large-scale clinical trials (Dilsiz, 2024). Consequently, manufacturers are increasingly required to integrate several techniques into complex downstream processing trains, balancing the high degree of purity required by regulatory authorities with the process economy necessary for commercial success.
Quality Control and the Need for Standardisation
Biomanufacturing follows the rule that "the product is the process." Due to inherent heterogeneity, minor variations in cell culture, passage number, or downstream processing can completely alter the final exosome product, making universal quality control (QC) standards difficult to establish.
Establishing a universal dosage remains a major hurdle. Unlike small molecules or monoclonal antibodies, exosome dosage complexity depends on debate over particle counts, protein loads, surface marker expression (e.g., CD9, CD63, CD81), or encapsulated active molecules. Regulatory approval from the FDA or EMA remains uncertain until these metrics are standardised. Furthermore, strict regulations require the removal of process-related impurities like host cell proteins (HCP) and host cell DNA (HCD). GMP factories face the challenge of consistently clearing these contaminants to safe levels without degrading the yield of intact EVs (Ahn et al., 2022).
The In Vivo Enigma: Pharmacokinetics and Biodistribution
Beyond manufacturing, EV therapeutics face critical unknowns regarding in vivo pharmacokinetics (PK). Tracking absorption, distribution, metabolism, and excretion is legally required for approval, yet uniquely difficult for natural biological nanoparticles. When administered intravenously, therapeutic EVs blend with background host exosomes, making tracking akin to finding a drop in the sea. Without accurate tracking, systemic clearance, tissue distribution, and target-site accumulation remain mere speculation (Kim et al., 2019).
To visualise real-time biodistribution, scientists rely on molecular imaging techniques like fluorescence imaging, MRI, and PET, typically by incorporating lipophilic fluorescent dyes or radioactive isotopes pre-injection (Kim et al., 2019). However, these methods face hurdles; lipophilic dyes can dissociate in vivo and bind to host cells or lipoproteins, creating false-positive signals. As Kim et al. (2019) emphasize, advanced quantitative methodologies for unmodified exosomes are essential. Until clearance rates by the liver and spleen are fully understood, establishing safe, effective human dosing regimens remains nearly impossible.
Conclusion
Extracellular vesicles hold undeniable potential to transform regenerative medicine, oncology, and immunotherapy, outperforming traditional synthetic nanoparticles through their unmatched biological design. However, translating this scientific promise into market-ready drugs faces a severe manufacturing shortfall rather than a lack of pre-clinical success.
To bridge this gap, the biopharmaceutical landscape must transition from academic-scale ultracentrifugation to scalable alternatives like tangential flow filtration and precision chromatography. Combined with rigid analytical standards for batch consistency and in vivo tracking, a unified framework across biotech firms, CDMOs, and regulators will finally unlock the true commercial and clinical potential of exosome science.
References
- Ahn, S.-H., Ryu, S.-W., Choi, H., et al. (2022). Manufacturing Therapeutic Exosomes: from Bench to Industry. Molecules and Cells, 45, 284–290. https://doi.org/10.14348/molcells.2022.2033
- Dilsiz, N. (2024). A comprehensive review on recent advances in exosome isolation and characterization: Toward clinical applications. Translational Oncology, 50, 102121. https://doi.org/10.1016/j.tranon.2024.102121
- Kim, D. H., Kothandan, V. K., Kim, H. W., et al. (2019). Noninvasive Assessment of Exosome Pharmacokinetics In Vivo: A Review. Pharmaceutics, 11(12), 649. https://doi.org/10.3390/pharmaceutics11120649
- Li, P., Kaslan, M., Lee, S. H., Yao, J., & Gao, Z. (2017). Progress in Exosome Isolation Techniques. Theranostics, 7(3), 789–804. https://doi.org/10.7150/thno.18133
Dr Deepika Arora is an accomplished professional with expertise in project management, process improvement, and operational excellence. She brings strong scientific expertise and experience in prolific biologics, contributing to innovation and quality-driven outcomes. With a commitment to continuous learning, she has led cross-functional initiatives across diverse industries and writes on leadership, strategy, and professional development.
Aditya Banerjee is a senior scientist specialising in stem cell biology, regenerative medicine, and translational research. His work focuses on GMP-compliant cell therapy manufacturing, exosome research, and quality systems. Passionate about advancing scientific innovation, he writes on emerging biotechnologies, laboratory excellence, and their translation into meaningful clinical applications.
